[go: up one dir, main page]

AR087020A1 - Polipeptidos de fusion de relaxina y usos de los mismos - Google Patents

Polipeptidos de fusion de relaxina y usos de los mismos

Info

Publication number
AR087020A1
AR087020A1 ARP120102381A ARP120102381A AR087020A1 AR 087020 A1 AR087020 A1 AR 087020A1 AR P120102381 A ARP120102381 A AR P120102381A AR P120102381 A ARP120102381 A AR P120102381A AR 087020 A1 AR087020 A1 AR 087020A1
Authority
AR
Argentina
Prior art keywords
relaxin
fusion polypeptides
polipeptides
same
present
Prior art date
Application number
ARP120102381A
Other languages
English (en)
Inventor
Linden Lars Dr
Leineweber Kirsten Dr
Tinnel Hanna Dr
Freiberg Christoph Dr
Wilmen Andreas Dr
Haupts Ulrich Dr
Trautwein Mark Dr
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of AR087020A1 publication Critical patent/AR087020A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente proporciona polipéptidos de fusión de relaxina A-L-B con un alineamiento no de tipo salvaje de la cadena A de relaxina y la cadena B de relaxina, en el que las cadenas A y B están conectadas mediante un péptido conector. La presente además proporciona polipéptidos de fusión de relaxina con semivida ampliada. Además, la presente proporciona secuencias de ácido nucleico que codifican los polipéptidos de fusión anteriores, los vectores que contienen a los mismos, las composiciones farmacéuticas y el uso médico de estos polipéptidos de fusión.
ARP120102381A 2011-07-01 2012-06-29 Polipeptidos de fusion de relaxina y usos de los mismos AR087020A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11172413 2011-07-01
EP11172681 2011-07-05

Publications (1)

Publication Number Publication Date
AR087020A1 true AR087020A1 (es) 2014-02-05

Family

ID=46489195

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102381A AR087020A1 (es) 2011-07-01 2012-06-29 Polipeptidos de fusion de relaxina y usos de los mismos

Country Status (14)

Country Link
US (1) US9382305B2 (es)
EP (1) EP2726502A1 (es)
JP (1) JP2014522641A (es)
KR (1) KR20140054009A (es)
CN (1) CN103930440A (es)
AR (1) AR087020A1 (es)
AU (1) AU2012280474A1 (es)
BR (1) BR112014000055A2 (es)
CA (1) CA2840552A1 (es)
HK (1) HK1199889A1 (es)
MX (1) MX2014000031A (es)
RU (1) RU2014103288A (es)
WO (1) WO2013004607A1 (es)
ZA (1) ZA201400762B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1199889A1 (en) 2011-07-01 2015-07-24 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
AR094147A1 (es) * 2012-12-27 2015-07-15 Bayer Pharma Aktiengellschaft Polipeptidos de fusion con actividad de relaxina y sus usos
CA2942514A1 (en) * 2013-03-15 2014-09-18 University Of Florida Research Foundation Compounds for treating neurodegenerative proteinopathies
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2015073727A1 (en) 2013-11-13 2015-05-21 Aequus Biopharma, Inc. Engineered glycoproteins and uses thereof
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
CN106413740A (zh) * 2014-06-13 2017-02-15 诺华股份有限公司 用于降低gdf‑15的serelaxin应用
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN104447982B (zh) * 2014-09-29 2017-08-25 深圳市辰瑞尔生物科技有限公司 一种人松弛素h2前体及其制备方法和应用
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TWI614030B (zh) * 2015-05-20 2018-02-11 免疫功坊股份有限公司 具有標的部分及效應部分的分子構建體
US11161891B2 (en) 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
TW202302631A (zh) * 2016-03-08 2023-01-16 日商武田藥品工業股份有限公司 可誘導性結合蛋白和使用方法
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
CN115837014A (zh) * 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018138170A1 (en) 2017-01-25 2018-08-02 Medimmune, Llc Relaxin fusion polypeptides and uses thereof
TW201837051A (zh) 2017-02-08 2018-10-16 美商必治妥美雅史谷比公司 包含藥物動力學增強劑之經修飾之鬆弛素(relaxin)多肽及其用途
WO2018213526A2 (en) 2017-05-18 2018-11-22 Biocapital Holdings, Llc Uv-resistant biological devices and extracts and methods for producing and using the same
KR102771251B1 (ko) 2017-09-08 2025-02-24 다케다 야쿠힌 고교 가부시키가이샤 제약된 조건적으로 활성화된 결합 단백질
CN109879969B (zh) * 2017-12-06 2024-04-09 天士力生物医药股份有限公司 一种hm-3融合蛋白及其应用
WO2019125975A1 (en) 2017-12-18 2019-06-27 Biocapital Holdings, Llc Biological devices and methods of use thereof for the detection of amyloid proteins
FI3746467T3 (fi) * 2018-01-31 2026-01-16 Sanofi Sa Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö
WO2019233842A1 (en) * 2018-06-08 2019-12-12 F. Hoffmann-La Roche Ag Peptidic linker with reduced post-translational modification
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
JP2022524338A (ja) 2019-03-05 2022-05-02 武田薬品工業株式会社 拘束され、条件的に活性化された結合タンパク質
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
MX2022013770A (es) * 2020-05-08 2023-04-03 Harvard College Relaxinas modificadas y metodos de uso de las mismas.
WO2021255127A1 (en) * 2020-06-17 2021-12-23 Medimmune Limited Heterodimeric relaxin fusions and uses thereof
CA3190606A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
US20240316154A1 (en) * 2021-02-02 2024-09-26 Eli Lilly And Company Half-life extending moieties and methods of using the same
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
JP2024522196A (ja) 2021-06-09 2024-06-11 ザ スクリプス リサーチ インスティテュート 長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法
MX2024005654A (es) 2021-11-11 2024-09-11 Tectonic Therapeutic Inc Análogos de la proteína de fusión de la relaxina-2 y métodos de usos de los mismos.
AU2022410335A1 (en) 2021-12-15 2024-07-18 Medimmune Limited Treatment using heterodimeric relaxin fusions
TW202438534A (zh) 2022-12-09 2024-10-01 瑞典商阿斯特捷利康公司 使用異二聚物鬆弛素融合體的給藥方案
IL323060A (en) 2023-03-03 2025-10-01 Astrazeneca Ab Pharmaceutical formulation containing heterodimeric relaxin fusion proteins and uses thereof
AU2024270919A1 (en) 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
NZ206534A (en) * 1982-12-13 1988-05-30 Florey Howard Inst Molecular cloning and characterisation of gene sequence coding for human relaxin
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
GB8430252D0 (en) 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
JP2875884B2 (ja) 1989-04-19 1999-03-31 ノボ ノルディスク アクティーゼルスカブ ポリペプチドの修飾に使用するための活性ポリアルキレンオキシドカーボネート
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
JP2857684B2 (ja) 1989-05-04 1999-02-17 ジェネンテク，インコーポレイテッド ヒトリラキシンの単離のための方法および組成物
EP0400472B1 (en) 1989-05-27 1996-04-03 Sumitomo Pharmaceuticals Company, Limited Process for preparing polyethylene glycol derivatives and modified protein.
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
EP0513332A4 (en) 1990-11-14 1993-03-17 Cargill, Incorporated Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
JPH06506217A (ja) 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5304473A (en) * 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
WO1994004193A1 (en) 1992-08-21 1994-03-03 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
IL104734A0 (en) 1993-02-15 1993-06-10 Univ Bar Ilan Bioactive conjugates of cellulose with amino compounds
AU7097094A (en) 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5473034A (en) 1994-03-18 1995-12-05 Hyogo Prefectural Government Method for producing protein-synthetic polymer conjugate and said conjugate produced thereby
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
WO1995033490A1 (en) 1994-06-02 1995-12-14 Enzon, Inc. Method of solubilizing substantially water insoluble materials
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CA2204726A1 (en) 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1996040791A1 (en) 1995-06-07 1996-12-19 Novo Nordisk A/S Modification of polypeptides
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JPH11514524A (ja) 1995-11-03 1999-12-14 リジェネロン ファーマシューティカルズ，インコーポレイテッド リラキシンおよびリガンドのインスリンファミリーに関連する分子の分子クローニングおよび特徴付け
CA2241567A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
ATE341344T1 (de) 1996-08-02 2006-10-15 Ortho Mcneil Pharm Inc Polypeptide mit einzelnem kovalent gebundenen n- terminalen wasserlöslichen polymer
DE69800640T2 (de) 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London Pegylationsverfahren
AU7266898A (en) 1997-04-30 1998-11-24 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
CN1250566C (zh) 1997-06-06 2006-04-12 协和发酵工业株式会社 化学修饰的多肽
IL133604A0 (en) 1997-07-16 2001-04-30 Novo Nordisk As Fused 1, 2, 4-thiadiazine derivatives, their preparation and use
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
CA2565375A1 (en) 1998-04-28 1999-11-04 Applied Research Systems Ars Holding N.V. Polyol-ifn-beta conjugates
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
CA2397200C (en) * 2000-02-09 2010-11-23 Connetics Corporation Use of relaxin to treat diseases related to vasoconstriction
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
DE10207072A1 (de) 2002-02-20 2003-08-28 Supramol Parenteral Colloids Stärkederivate, ihre Konjugate und Verfahren zur Herstellung derselben
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
CN1929865B (zh) 2004-03-11 2011-11-16 费森尤斯卡比德国有限公司 羟烷基淀粉和蛋白质的接合物
ES2821832T3 (es) 2004-11-12 2021-04-27 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
WO2009140659A2 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of treating dyspnea associated with acute heart failure
WO2010054699A1 (en) 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
US8389475B2 (en) * 2009-08-10 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Relaxin analogs
US20110243943A1 (en) 2010-04-02 2011-10-06 Athena Discovery, Inc. Treatment using relaxin-fusion proteins with extended in vivo half-lives
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
SMT201900495T1 (it) 2010-08-17 2019-11-13 Ambrx Inc Polipeptidi di relaxina modificati e loro usi
HK1199889A1 (en) 2011-07-01 2015-07-24 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
KR20140039257A (ko) 2011-07-08 2014-04-01 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신을 방출하는 융합 단백질 및 이의 용도

Also Published As

Publication number Publication date
CA2840552A1 (en) 2013-01-10
EP2726502A1 (en) 2014-05-07
US20140187491A1 (en) 2014-07-03
HK1199889A1 (en) 2015-07-24
CN103930440A (zh) 2014-07-16
MX2014000031A (es) 2014-07-09
JP2014522641A (ja) 2014-09-08
KR20140054009A (ko) 2014-05-08
WO2013004607A1 (en) 2013-01-10
ZA201400762B (en) 2016-02-24
RU2014103288A (ru) 2015-08-10
US9382305B2 (en) 2016-07-05
AU2012280474A1 (en) 2014-01-16
BR112014000055A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
AR087020A1 (es) Polipeptidos de fusion de relaxina y usos de los mismos
AR129651A2 (es) Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CY1120622T1 (el) Μεθοδοι και συνθεσεις για επαγωγη μιας ανοσιακης αποκρισης ως προς egfrviii
CR20160117A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
MX2019008148A (es) Uso de peptidos glp-1 de accion prolongada.
BRPI0923346A2 (pt) Proteinas em super-helice antiparalela de cadeia simples
AR086998A1 (es) Coagonistas del receptor de glucagon/glp-1
MX377804B (es) Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc).
MX342171B (es) Peptido o complejo peptidico que se une a integrina ?2 y metodos y usos que implican a los mismos.
MA34077B1 (fr) Nouveau peptides et procedes pour leur preparation, ain que leur utilisation
PE20151745A1 (es) Polipeptidos que tienen actividad de lisozima y polinucleotidos que los codifican
MX2016015952A (es) Constructos de anticuerpo multiespecifico.
CL2013003634A1 (es) Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso
MX374682B (es) Moléculas de unión a 4-1bb.
MX376234B (es) Anticuerpo anti-ctla-4 como modulador inmune.
DOP2014000199A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
BR112013003522A2 (pt) "polipeptídeos relaxina modificados compreendeendo um aminoácido não codificado naturalmente, uso, método de preparação, bem como ácido nucleico codificando os mesmos"
AR087070A1 (es) Proteinas de fusion liberadoras de relaxina y usos de las mismas
EA201391764A1 (ru) Агонисты рецептора glp-1/глюкагона длительного действия
MX369545B (es) Receptor de antígeno químerico y métodos para usarlo.
MX357403B (es) Polipeptidos de factor viii quimericos y usos de los mismos.
EA201500659A1 (ru) Ацетилтрансферазы и их применение для получения каротиноидов
MX362432B (es) Variantes de oxm pegilada.
BR112012020863A2 (pt) formas de rifaximina e usos das mesmas
UY35703A (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure